Teva Pharmaceutical Industries Lt.../ US8816242098 /
| 2024-11-12 10:10:00 PM | Chg. -0.26 | Volume | Bid11:40:37 PM | Ask11:40:37 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 17.11USD | -1.50% | 7.4 mill. Turnover: 75.82 mill. |
17.10Bid Size: 2,500 | 17.41Ask Size: 100 | -USD | - | - |
Assets
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 6,868 | 6,436 | 6,296 | 5,982 | 5,739 | ||||||
| Intangible Assets | 14,005 | 11,232 | 8,923 | 7,466 | 6,270 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | - | - | 37,635 | 35,093 | 31,955 | ||||||
| Inventories | 4,731 | 4,422 | 4,403 | 3,818 | 3,833 | ||||||
| Accounts Receivable | 5,822 | 5,676 | 4,581 | 4,529 | 3,696 | ||||||
| Cash and Cash Equivalents | 1,782 | 1,975 | 2,177 | 2,165 | 2,801 | ||||||
| Current Assets | 13,794 | 13,464 | 13,005 | 12,573 | 12,051 | ||||||
| Total Assets | 60,683 | 57,470 | 50,640 | 47,666 | 44,006 | ||||||
Liabilities
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 1,853 | 1,718 | 1,756 | 1,686 | 1,887 | ||||||
| Long-term debt | - | - | 22,731 | 21,617 | 19,103 | ||||||
| Liabilities to Banks | 2,216 | 2,345 | 3,188 | 1,426 | - | ||||||
| Provisions | 2,140 | 1,096 | 964 | 784 | - | ||||||
| Liabilities | 44,889 | 42,407 | 39,579 | 36,422 | 35,315 | ||||||
| Share Capital | 56 | 56 | 57 | 57 | 57 | ||||||
| Total Equity | 14,707 | 13,972 | 11,061 | 11,244 | 8,691 | ||||||
| Minority Interests | 1,087 | 1,091 | 1,035 | 966 | 794 | ||||||
| Total liabilities equity | 60,683 | 57,470 | 50,640 | 47,666 | 44,006 | ||||||
Income Statement
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 18,854 | 16,887 | 16,659 | 15,878 | 14,925 | ||||||
| Depreciation (total) | - | - | 1,557 | 1,330 | 1,308 | ||||||
| Operating Result | -1,637 | -443 | -3,572 | 1,716 | -2,099 | ||||||
| Interest Income | -959 | -822 | 834 | 1,058 | 966 | ||||||
| Income Before Taxes | -2,596 | -1,265 | -4,406 | 658 | -3,065 | ||||||
| Income Taxes | -195 | -278 | -168 | 211 | -638 | ||||||
| Minority Interests Profit | 322 | 1 | -109 | 39 | -53 | ||||||
| Net Income | -2,150 | -999 | -3,990 | 417 | -2,353 | ||||||
Per Share
Cash Flow
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 2,446 | 748 | 1,216 | 798 | 1,590 | ||||||
| Cash Flow from Investing Activities | 1,866 | 1,355 | 863 | 1,523 | 656 | ||||||
| Cash Flow from Financing | -3,351 | -1,926 | -1,885 | -2,172 | -1,487 | ||||||
| Decrease / Increase in Cash | 819 | 193 | 202 | 21 | 636 | ||||||
| Employees | 42,535 | 40,039 | 40,216 | 37,537 | - | ||||||
